Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
GLP-1: An Overview Glucagon-like peptide-1 (GLP-1) agonists act by stimulating insulin secretion in hyperglycemic states, suppressing glucagon secretion in hyperglycemic or euglycemic states, delaying gastric emptying, decreasing appetite, and reducing body weight
Many clinicians consider it a first-line treatment due to its well-balanced efficacy and safety profile, especially when compared to older agents with higher rates of sedation and metabolic risk
Quick Answer: Zepbound does not require weaning and can be stopped abruptly without dangerous withdrawal, though gradual discontinuation may help some patients adjust to appetite changes and implement lifestyle strategies
The drug is also sold under the brand Wegovy, which is formulated for weight loss alone
Tirzepatide which targets both GLP-1 and GIP receptors has shown even more dramatic early results: weight loss of 1020 kg and insulin dose reductions exceeding 30% in observational and phase 2 data, with improved CGM time in range
